Palo Alto-based Theranos Inc. is back in the news after informing doctors and patients of errors related to thousands of blood tests over the past two years, according to the San Francisco Business Times.
No patients were harmed. The company admitted the corrections to the Centers for Medicare and Medicaid Services, which will be ruling on sanctions against the company following previous problems at one of their California labs.
"Excellence in quality and patient safety is our top priority and we’ve taken comprehensive corrective measures to address the issues CMS raised in their observations," Brooke Buchanan, a Theranos spokeswoman, told the news outlet. "As these matters are currently under review, we have no further comment at this time."
The company has touted their finger-prick technology as innovative and game-changing, but its effectiveness has been questioned.
In an unrelated case, the company is being criminally investigated by the Securities and Exchange Commission, and could face civil suits.